Some of the figures in the detail are interesting:
Forecasting Sales:
.........$M
2011:...16.4
2012:...54.1
2013:...54.6
From Chart 1, the 2012 & 2013 sales represent royalties of about $25M and $20M from Relenza and Inavir.
EBITDA:
.........$M
2011:...(17.9)
2012:... 17.6
2013:... 37.1
Cash & deposits balance 30 June
..........$M
2011:... 88.5
2012:... 97.1
2013:...123.0
They indicate that the key issue is an upcoming decision on non-dilutive funding in relation to funding of the LANI trial.
Regards
SP
- Forums
- ASX - By Stock
- BTA
- rbsmorgans:biota " buy"
rbsmorgans:biota " buy", page-8
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)